Cellectar Biosciences, Inc.
CLRB
$3.69
$0.071.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -36.20% | 22.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.66% | -5.68% | |||
| Operating Income | 19.66% | 5.68% | |||
| Income Before Tax | 18.43% | 17.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 18.43% | 17.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.43% | 17.51% | |||
| EBIT | 19.66% | 5.68% | |||
| EBITDA | 19.79% | 5.72% | |||
| EPS Basic | 58.50% | 21.24% | |||
| Normalized Basic EPS | 58.50% | 21.24% | |||
| EPS Diluted | 58.41% | 21.15% | |||
| Normalized Diluted EPS | 58.50% | 21.24% | |||
| Average Basic Shares Outstanding | 96.54% | 4.74% | |||
| Average Diluted Shares Outstanding | 96.54% | 4.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||